The raised guidance and accelerating Breast segment growth signal strong commercial execution and expanding market access. Monitor the Q3 earnings call for updates on Aetna coverage decision and prostate clinical development progress, which could provide further catalysts. The stock's 94% analyst bullish consensus suggests limited downside, but watch for margin pressure from continued investment in sales force expansion.
Price Chart
Executive Summary
Axogen reported Q2 2026 revenue of $69.7M (+23.1% YoY), slightly above the $67.1M consensus, and adjusted EPS of $0.12, in line with estimates. The company raised its full-year 2026 revenue guidance to at least $279M (24% growth), up from the prior $270M (20% growth) target, driven by accelerating Breast segment growth (>50% YoY) and expanding commercial insurance coverage. The stock is likely to react positively to the guidance raise and strong top-line momentum, though GAAP net loss widened to -$0.03/share vs +$0.01 a year ago, and adjusted EBITDA margin compressed to 12.1% from 16.3% due to increased investment in sales force and R&D.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $69.7M, +23.1% YoY, vs consensus $67.1M
- Adjusted EPS $0.12, in line with consensus
- Full-year 2026 revenue guidance raised to at least $279M (24% growth), from prior $270M (20% growth)
- Breast segment growth >50% YoY, driving product mix shift and gross margin compression to 72.7% from 74.2%
- GAAP net loss -$1.5M (-$0.03/share) vs net income $0.6M ($0.01/share) in Q2 2025
- Adjusted EBITDA $8.4M, margin 12.1% vs 16.3% a year ago
- Cash, equivalents, restricted cash, and investments $113.4M; no debt outstanding
- Avance commercial payer coverage ~86% of US covered lives; CMS proposed CY2027 payment rule increases nerve repair rates
- Initiated Nerve-RESTORE Level 1 clinical study comparing Avance to autograft; REPOSE study published
- Acquired minority stake in Trace Biosciences for nerve-specific imaging technology
Financial Impact
Revenue guidance raised by $9M at midpoint (from $270M to $279M), representing ~3.3% incremental upside vs prior outlook
Risk Factors
- Gross margin compression to 72.7% from 74.2% due to unfavorable product mix from faster-growing Breast segment
- Adjusted EBITDA margin declined 420bps YoY to 12.1% as operating expenses grew faster than revenue (30.9% vs 23.1%)
- GAAP net loss widened to -$1.5M from +$0.6M in prior year quarter
- Dependence on continued commercial insurance coverage expansion for Avance; Aetna decision still pending
- Prostate market development remains early stage with only 100+ procedures and 10+ active clinical sites
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000805928-26-000091 |
| Exhibit: ex993q22026_axgnxcorpora.htm | 0000805928-26-000091 |
| Exhibit: ex992axgn_q2earningsrele.htm | 0000805928-26-000091 |
| Document: axgn-20260729.htm | 0000805928-26-000091 |
| Document: 0000805928-26-000091-index-headers.html | 0000805928-26-000091 |
| Document: 0000805928-26-000091-index.html | 0000805928-26-000091 |
| Document: 0000805928-26-000091.txt | 0000805928-26-000091 |
| 8-K Data (Synthetic) | 0000805928-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | 424B5 | $42.16 $44.23 | ▲ +4.91% | ▲ +5.13% | $37.75 (−10.46%) |
Sep 10, 2026 22d ago | 8-K | $41.85 $45.29 | ▲ +8.21% | ▲ +8.71% | $37.75 (−9.80%) |
Sep 10, 2026 22d ago | Press Release | $41.85 $45.29 | ▼ −8.21% | ▼ −8.71% | $37.75 (+9.80%) |
Sep 10, 2026 22d ago | Press Release | $41.85 $45.29 | ▲ +8.21% | ▲ +8.71% | $37.75 (−9.80%) |
Aug 12, 2026 7w ago | Insider Cluster | $49.67 $48.93 | ▼ −1.49% | ▼ −1.05% | $37.75 (−24.00%) |
Aug 11, 2026 7w ago | Institutional Cluster | $49.67 $48.93 | ▼ −1.49% | ▼ −1.05% | $37.75 (−24.00%) |
Jul 29, 2026 9w ago | 8-K | $41.37 $45.22 | ▲ +9.31% | ▲ +3.78% | $37.75 (−8.75%) |
Jul 15, 2026 11w ago | Press Release | $38.72 $39.37 | ▲ +1.68% | ▲ +2.66% | $37.75 (−2.51%) |
Jul 9, 2026 12w ago | Institutional Cluster | $43.62 $39.78 | ▼ −8.81% | ▼ −8.68% | $37.75 (−13.46%) |
Jun 12, 2026 16w ago | Institutional Cluster | $43.00 $44.84 | ▲ +4.28% | ▲ +3.61% | $37.75 (−12.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access